Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and efficacy of new and emerging products in the aesthetics portfolio and insights on the aesthetic mindset of an emerging patient population. Data from Safety and Efficacy of TrenibotulinumtoxinE Following Repeat Treatments for Glabellar Lines: Findings From an Open-Label Phase 3 Study report findings from an 18-week, open-label, Phase 3 study evaluating the safety and efficacy of repeat TrenibotE (up to 3 open-label treatments) for glabellar lines showed a consistent safety profile. TrenibotE is an investigational first-in-class botulinum neurotoxin serotype E characterized by rapid results, as early as 8 hours after administration (earliest assessment time), and shorter duration of effect of 2-3 weeks.

If approved, TrenibotE will be the first neurotoxin of its kind available to patients. Key findings include: TrenibotE was well-tolerated over 3 sequential open-label treatments, showing a consistent safety profile, no new safety concerns, and no neutralizing antibody development. TrenibotE rapidly reduced glabellar line severity, with consistent efficacy over 3 sequential open-label treatments based on investigator and participant assessments.

Data in Population Trends in Facial Aesthetic Concerns Among Patients Receiving GLP-1 Agonists for Weight Loss was obtained from an electronic survey of health care professionals in the United States who had experience treating patients with aesthetic concerns associated with GLP-1 agonists. The population of GLP-1 patients seeking aesthetic treatment is growing rapidly across all aesthetic specialties, with an estimated 52% of GLP-1-treated patients expressing concern about their facial appearance as they move through GLP-1 treatment. Key findings include: Aesthetics health care professionals reported 32% of GLP-1-treated patients are new to their practice.

Top two barriers preventing these patients from receiving aesthetic treatments include cost (82%) and fear of unnatural results (58%). Patients receiving GLP-1 treatment were reported to be predominantly white (64%), female (70%), and 30-49 years of age (56%).